Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 11/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13130594 | 0.83 | CYP2A6 (0.61) | PTGS1CYP2A6CYP3A4CYP2B6CYP2C19 | |
| SCHEMBL10829180 | 0.82 | CYP2A6 (0.48) | PTGS1CYP2A6CYP3A4CYP2B6CYP2C19 | |
| SCHEMBL1661929 | 0.79 | PTGS1 (0.71) | PTGS1CYP2A6PTGS2 | |
| SCHEMBL8076141 | 0.77 | CYP2A6 (0.55) | CYP2A6CYP3A4CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL15332349 | 0.77 | PTGS1 (0.56) | PTGS1CYP2A6ALDH1A1TYRCYP2A13 | |
| SCHEMBL4373549 | 0.77 | PTGS1 (0.51) | PTGS1CYP2A6BRD4ALDH1A1TYR | |
| SCHEMBL4948071 | 0.76 | PTGS1 (0.54) | PTGS1CYP2A6ALDH1A1TYRCYP2A13 | |
| SCHEMBL11480738 | 0.75 | CYP2A6 (0.42) | PTGS1CYP2A6CYP3A4CYP2B6CYP2C19 | |
| SCHEMBL4375211 | 0.74 | PTGS1 (0.53) | PTGS1CYP2A6ALDH1A1TYR | |
| SCHEMBL10407505 | 0.74 | CYP2A6 (0.52) | CYP2A6CYP3A4CYP2B6CYP2C19CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1594856-A1 | CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004060882-A1 | CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | CNR1, CNR2, OPRL1 | PTGS1 369/4885CYP2A6 449/4885CYP3A4 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.